tirzepatide hba1c reduction Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study Adding tirzepatide to basal insulin

"This substance is not approved for sale or use as a tanning agent in Australia and has not been assessed for safety or quality," it said

Headaches , sleep disturbances , body aches , and anxiety are reported side effects that should be weighed against the significant weight loss benefits

For a broader look at the SURMOUNT trial data and what it means clinically, the article on the SURMOUNT trials covers the key findings in detail

Is that wrong

The American Diabetes Association (ADA) 2024 Standards of Care support GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists, including tirzepatide, particularly in patients with: Established atherosclerotic cardiovascular disease or high cardiovascular risk Chronic kidney disease Need for substantial A1c reduction (tirzepatide typically reduces A1c by 1.5-2.5%) Desire to avoid weight gain or achieve weight loss Inadequate glycemic control on metformin or other oral agents Tirzepatide is not approved for type 1 diabetes or diabetic ketoacidosis